Pub. Date : 2006 Nov 15
PMID : 16857985
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. | lestaurtinib | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 2 | A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. | lestaurtinib | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 3 | We undertook a phase 2 trial of the FLT3-selective tyrosine kinase inhibitor lestaurtinib (CEP701) used as monotherapy in untreated older patients with AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation status. | lestaurtinib | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 4 | We undertook a phase 2 trial of the FLT3-selective tyrosine kinase inhibitor lestaurtinib (CEP701) used as monotherapy in untreated older patients with AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation status. | lestaurtinib | fms related receptor tyrosine kinase 3 | Homo sapiens |